Segment Information - Schedule of Significant Segment Expense Categories (Details) - USD ($) $ in Thousands	3 Months Ended						9 Months Ended
	Sep. 30, 2025	Jun. 30, 2025	Mar. 31, 2025	Sep. 30, 2024	Jun. 30, 2024	Mar. 31, 2024	Sep. 30, 2025	Sep. 30, 2024
Segment Reporting Information [Line Items]
Research and development personnel-related expense	$ (50,334)			$ (24,685)			$ (124,416)	$ (71,874)
Stock-based compensation expense	(9,514)			(4,332)			(24,297)	(12,481)
Net loss	(62,321)	$ (55,247)	$ (34,085)	(26,599)	$ (26,352)	$ (26,949)	(151,653)	(79,900)
Significant Segment Expense Category [Member]
Segment Reporting Information [Line Items]
Commercial expense	(3,928)			(555)			(8,509)	(1,060)
General and administrative expense	(8,343)			(4,964)			(23,074)	(14,664)
Stock-based compensation expense	(9,514)			(4,332)			(24,297)	(12,481)
Other Segment Items [Member]
Segment Reporting Information [Line Items]
Other segment items	5,375			6,257			17,399	15,270
Key Measure of Segment Profit or Loss [Member]
Segment Reporting Information [Line Items]
Net loss	(62,321)			(26,599)			(151,653)	(79,900)
Bitopertin [Member] \| Significant Segment Expense Category [Member]
Segment Reporting Information [Line Items]
Research and development personnel-related expense	(11,833)			(7,261)			(43,954)	(20,742)
DISC-0974 [Member] \| Significant Segment Expense Category [Member]
Segment Reporting Information [Line Items]
Research and development personnel-related expense	(7,369)			(5,671)			(18,105)	(12,731)
DISC-3405 [Member] \| Significant Segment Expense Category [Member]
Segment Reporting Information [Line Items]
Research and development personnel-related expense	(11,910)			(3,254)			(15,486)	(11,823)
Other Research [Member] \| Significant Segment Expense Category [Member]
Segment Reporting Information [Line Items]
Research and development personnel-related expense	(4,095)			(1,233)			(9,030)	(4,891)
Internal Research and Development [Member] \| Significant Segment Expense Category [Member]
Segment Reporting Information [Line Items]
Research and development personnel-related expense	$ (10,704)			$ (5,586)			$ (26,597)	$ (16,778)

Disc Medicine, Inc. 10-Q